Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DW9801 in Primary Dysmenorrhea
NCT04541134Phase 3Unknown
- Sponsor
- Daewon Pharm
- Start
- Sep 2020
- Primary completion
- Aug 2021
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of pelubiprofen in primary dysmenorrhea (PD) (2 arms), sponsored by Daewon Pharm. Primary endpoints: Total Pain Relief over 8 hours at Day 1 and Sum of Pain Intensity Difference over 8 hours at Day 1. Status: unknown.
02
Drugs
pelubiprofen
03
Conditions
primary dysmenorrhea (PD)
Beyond the preview
Go deeper on NCT04541134.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04541134.